Freselestat is primarily used as a therapeutic agent in the treatment of acute pancreatitis. It functions as a neutrophil elastase inhibitor, targeting the excessive activity of this enzyme, which is known to contribute to tissue damage and inflammation in the pancreas. By inhibiting neutrophil elastase, Freselestat helps to reduce the severity of pancreatic injury, thereby improving patient outcomes. It is often administered intravenously in clinical settings to ensure rapid and effective delivery. Additionally, its anti-inflammatory properties make it a potential candidate for managing other conditions where neutrophil elastase plays a detrimental role, such as acute lung injury or sepsis. Research continues to explore its broader applications in inflammatory and tissue-damaging diseases.